MILL VALLEY, Calif., Oct. 16, 2019 /PRNewswire/ — Every year, nearly 800,000 Americans have a heart attack. Heart disease now accounts for one in four deaths, according to the Centers for Disease Control and Prevention. When patients have heart attack symptoms, the most important factor in a successful outcome is how quickly […]
Other News
Abbott Reports Third-Quarter 2019 Results
– Third-quarter sales growth of 5.5 percent; organic sales growth of 7.6 percent – Exceptional growth across key platforms of FreeStyle Libre, MitraClip and Alinity – Continues to strengthen portfolio with a steady cadence of new product approvals, reimbursement coverage and clinical data ABBOTT PARK, Ill., Oct. 16, 2019 /PRNewswire/ — Abbott […]
Philips introduces new 200mm and 150mm Stellarex 0.035” low-dose drug-coated balloons to broaden treatment options for peripheral artery disease patients
Stellarex’s unique coating enables a low therapeutic drug dose and has demonstrated a significant treatment effect and high safety profile Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced two new balloons to its Stellarex 0.035” low-dose drug-coated balloon (DCB) portfolio. The new 200mm […]
BioSig Opens a Technology Development Office in Rochester, MN
Westport, CT, Oct. 15, 2019 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or “The Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company is opening […]
Medicure Announces SMILE™-HF Study Demonstrates Use of ReDS™ Results in 58% Reduction in Hospital Readmission Rate
WINNIPEG, Oct. 15, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the primary results of the late-breaking SMILETM-Heart Failure (SMILE-HF) Clinical Trial which was presented at the recent Heart Failure Society of America (“HFSA”) conference in Philadelphia, PA by Dr. William T. Abraham, the […]
Neovasc Announces Notice of US Patent Granted for Tiara™ Transcatheter Device for Treatment of Severe Mitral Regurgitation
VANCOUVER, Oct. 15, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the United States Patent […]
CHF Solutions Announces that James A. Haley Veterans’ Hospital Receives Final Approval To Initiate Heart Failure Outpatient Study utilizing Aquadex FlexFlow® System
First Study of Aquadex FlexFlow System Sponsored by United States Veterans Administration for Aquapheresis Treatment in Patients Suffering from Fluid Overload. First patient enrollment expected in the fourth quarter of 2019. EDEN PRAIRIE, Minn., Oct. 10, 2019 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), today announced that James A. Haley […]
Pi-Cardia Appoints Prof. Jacques Séguin As Chairman
REHOVOT, Israel, Oct. 14, 2019 /PRNewswire/ — Pi-Cardia Ltd. (www.pi-cardia.net), announced today the appointment of Prof. Jacques Séguin, former CoreValve Founder and CEO and serial medical device entrepreneur, as Chairman of its Board of Directors. Jacques Séguin is a professor of Cardiac Surgery at Paris University and holds, in addition to his MD, a PhD […]
CINDE Announces: Edwards Lifesciences Invests $100 million to Expand its Operations in Costa Rica
SAN JOSÉ, Costa Rica, Oct. 10, 2019 /PRNewswire/ — Edwards Lifesciences Corporation, a world leader in innovations for structural heart disease and critical care monitoring aimed at patients, expanded its presence in Costa Rica with a $100 million investment and the addition of 500 new jobs by the end of 2020. The brand new facility is located […]
Admedus Inks $A36.2M Deal for CardioCel And VascuCel Patch Business
Transaction Highlights: Admedus has sold the distribution rights to its CardioCel® and VascuCel® product range for $A36.2 million (including all earnouts) to LeMaitre Vascular Inc. $A22.8M upfront payment plus two instalments of $A1m each after 12 months and 36 months Up to $A11.4M on earn-out payments for a total $A36.2M (at the current $US0.67/$A1 rate), subject to achievement of certain milestones Up to […]



